3D Systems announced its acquisition of Volumetric and its plans to keep operations in Houston. Photo via Jordan Miller/Rice University

Houston-based Volumetric Biotechnologies has gone from startup to nine-figure acquisition in a mere three years.

Volumetric, which makes 3D-printed human organs and tissues, agreed October 27 to be purchased by publicly traded 3D Systems, a Rock Hill, South Carolina-based company that specializes in 3D technology, for as much as $400 million. The cash-and-stock deal, expected to be completed this year, will provide $45 million at closing and up to $355 million if Volumetric reaches certain benchmarks.

"Volumetric is already successful in its space with innovative light-based bioprinting," says Jeffrey Graves, president and CEO of 3D Systems. "This acquisition and integration of Volumetric into the 3D Systems family advances our commitment to health care."

Founded in 2018, Volumetric is a privately held spin-out of Rice University's bioengineering department. Its co-founders are Jordan Miller, the company's president, and Bagrat Grigoryan, the chief operating officer. Volumetric participated in the San Francisco-based accelerator Y Combinator in 2020. Investors include two health care nonprofits, the Methuselah Foundation and Methuselah Fund.

Miller, an associate professor of bioengineering at Rice University, will join 3D Systems as chief scientist for regenerative medicine, and Grigoryan will come aboard as vice president of regenerative medicine.

In conjunction with the acquisition, 3D Systems and business partner United Therapeutics, based in Manchester, New Hampshire, will conduct R&D for organ and tissue manufacturing at Volumetric's 20,000-square-foot facility in Houston's East End Maker Hub. Last December, Volumetric moved its operations to the hub. The startup produces human organs and tissues like the liver, kidney, pancreas, lung, and heart using a combination of human cells and medical-grade plastics.

"The vital organs inside of the human body are the most complicated structures in the known universe," Miller says in a news release. "Just as a vibrant city needs roads, a vital organ needs vasculature. Our work to date at Volumetric has focused on 3D bioprinting the intricate blood vessel architecture that is crucial for the function of these organs."

Grigoryan says manufacturing human organs represents a "transformative opportunity" to combat organ diseases.

"Broadening our team's ability to deliver on the promise of organ therapy is a win for patients and medical care around the world, as well as Volumetric shareholders who believed in our promise from early phase development," Grigoryan says.

Human-tissue printing technology, blockchain networks, health care solutions, game-changing software — all this innovation and more is coming out of Houston startups. Courtesy photos

Editor's Picks: Top 10 Houston startup feature stories of 2019

2019 in review

Thousands of startups call Houston home. According to the Greater Houston Partnership's data, the Houston area added 11,700 firms between 2013 to 2018. And, if you consider Crunchbase's tally, at the end of 2018, Houston had over 1,400 tech startups on the investment tracking website's radar.

This past year, InnovationMap featured profiles on dozens of these Houston startups — from blockchain and software companies to startups with solutions in health care and oil and gas. Here are 10 that stood out throughout 2019.

Topl — a blockchain startup connecting every step of the way

Houston-based Topl can track almost anything using its blockchain technology. Getty Images

For Topl, 2019 was a year of laying the groundwork. In a January 2019 article on InnovationMap, Kim Raath, president of the Houston-based blockchain company, explained that Topl's mission originated out of the fact that 60 percent of the world lives on $10 a day — and it's in the poorest regions of the world where it's the hardest to get funding for a new business.

Raath says that in her experience backpacking and volunteering all around the world she learned that banks are too overwhelmed to evaluate these potential businesses. Topl has created a technology where banks can easily generate a report on these entrepreneurs that evaluates and makes a loan or investment recommendation on the business.

"We are a generation that wants a story," she says. "We want an origin, and don't want to be fooled. And, because you might be able to reduce the cost by having this transparency, you might be able to bring down the cost on both sides."

Later that year, the company closed a 20 percent oversubscribed $700,000 seed round. With the money, Topl will be able to grow its platforms, provide better product features, and increase marketing efforts. Topl's customers are drawn to the technology because of the business efficiency the blockchain adds to their supply chain, but they are also excited about how having this technology differentiates them from their competition. Raath says she's interested in growing Topl's ability to do joint marketing campaigns with their customers.

Incentifind — finding green incentives for commercial and residential building

Natalie Goodman founded Incentifind, which connects home builders and commercial developers with green incentives. Courtesy of Incentifind

When asked about the origin story of IncentiFind — a Houston-based startup that connects real estate developers and home builders with green construction incentives — founder Natalie Goodman doesn't mince words.

"We're a complete accident," Goodman tells InnovationMap in an interview in March. "I'm an architect. We didn't set out to have a startup."

IncentiFind's mission is to increase the amount of green developments and construction projects in the U.S. The company is equipped with a massive database of green incentives that are offered by utility, county, city, state and federal agencies. Many home builders or commercial developers don't take advantage of green incentives because they're simply not aware of them, Goodman says. Commercial developers can expect to spend around $1,500 with IncentiFind, while homeowners can expect to spend between $50 and $150.

Lazarus 3D — 3D printed organs to better train surgeons

Lazarus 3D is using 3D printing to help advance surgeons' skills. Photo via laz3d.com

It's pretty standard for surgeons in training to practice complicated surgeries on produce — slicing bananas open and sewing grapes back together. But for a pair of Baylor College of Medicine-educated doctors, that didn't seem like sufficient prep for working with living bodies; fruit surgery was not fruitful enough. In 2014, Drs. Jacques Zaneveld and Smriti Agrawal Zaneveld founded Lazarus3D to build a better training model — and layer by layer, they created models of abs and ribs and even hearts with a 3D printer.

"We adapted pre-existing 3D printing technology in a novel proprietary way that allows us to, overnight, build soft, silicone or hydrogel models of human anatomy," Jacques, who serves as CEO, tells InnovationMap in July. "They can be treated just like real tissue."

This year, the company grew to seven people and aims to expand even more to add to its sales and manufacturing teams. Having been funded mostly by friends and family investors, Lazarus3D plans enter its first equity round to raise $6 million, InnovationMap reported last summer.

Mental Health Match — connecting people to the right therapists

Ryan Schwartz realized online dating was easier than finding a therapist. He created a tool to change that. Courtesy of Mental Health Match

Nearly five years ago, Ryan Schwartz sat in a coffee shop in crisis mode. His mother had just died suddenly and he was struggling to find an appropriate therapist. Across the table, his friend sat making a profile on a dating app. Quickly, her endeavor was complete and she was ready to swipe right, but Schwartz was still on the hunt for mental help.

"In two minutes she could have a profile matching her with a partner potentially for the rest of her life and I was sitting there for hours and hours trying to find a therapist," he told InnovationMap in June. "I thought it should be easier to find a therapist than a life partner. That's what sent me on my journey."

That journey reached a watershed last month when Schwartz launched Mental Health Match, a website designed to pair patients with their ideal therapist. The idea gained traction as Schwartz described it to people he met and found that many said they had experienced similar difficulties in finding the right practitioner for their needs.

Grab — making ordering food at the airport easier

Houston-based Grab makes it so you're waiting in one less line at the airport. Getty Images

Most airport lines are unavoidable, but a Houston startup has cut out at least some of those lines with its mobile ordering app. Houston-based software company Grab was founded by Mark Bergsrud in 2015, who worked in senior leadership roles for almost 20 years at Continental Airlines and then United Airlines, following the merger. For Bergsrud, Grab feels like another major mobile game changer the industry experienced.

"I spent many years thinking about the travel experience and how to make it better and faster," Bergsrud told InnovationMap in July. "This feels like how mobile check in felt. There was a problem customers didn't know they had — check in wasn't that difficult anyway, but to be able to have that control, people love it."

Grab now has a presence in over 37 airports around the world, including Dallas and Austin though, ironically, not yet either of Houston's airports. Expansion is in the works for Grab, which closed a multimillion-dollar Series A round this year — London-based Collinson Group was the sole contributor.

NurseDash — An app that connects nurses to shifts

Houston-based NurseDash is the Uber of staffing nursing shifts in medical facilities. Photo via nursedash.com

Across the country, medical facilities are short on nurses. Agencies play a role in matchmaking nurses to open shifts, but agencies charge a high percentage for placement and lack transparency, says Andy Chen, former CFO for Nobilis Health Corporation. That's why he and Jakob Kohl created their app, NurseDash in 2017. The project manager for the app is in New York, but official headquarters in Houston's Galleria area, where a staff of five works with the team spread out around the world.

Since its debut, NurseDash has attracted 40 facilities in Houston, InnovationMap reported in May, including hospitals, surgery centers, and senior living, and about 400 nurses. Chen says he isn't sure just what to call his technology yet, but compares it to the ride hailing of Uber or Lyft and calls it "a virtual bulletin board."

Syzygy — hydrogen cells battery to minimize natural gas

Trevor Best, CEO of Syzygy Plasmonics, walked away from EarthX $100,000 richer. Photo via LinkedIn

A Houston technology company is doing something that, for many decades, wasn't thought to be possible. Syzygy Plasmonics is creating a hydrogen fuel cell technology that produces a cheaper source of energy that releases fewer carbon emissions. The hydrogen-fueled technology originated out of research done over two decades by two Rice University professors, Naomi Halas and Peter Nordlander.

Syzygy's technology, CEO Trevor Best told InnovationMap in August, is structured more like a battery than that of a combustion engine. Inside the technology, there are cells, lights, and mirrors making as bright as possible, which then spurs a reaction that creates energy. It has the potential to be cheaper — it's made with cheaper materials — and, of course, cleaner than traditional fueling technology with fewer carbon emissions released.

This new photocatalytic chemical reactor has the potential to shake up the industrial gas, chemical, and energy industries — something that hasn't gone unnoticed by investors. Syzygy just closed a $5.8 million Series A round, and the funds will allow for Syzygy to continue to develop its technology and grow its team. Best tells InnovationMap that he expects to launch a full-size pilot by the end of 2020 and is already in talks with potential clients who are interested in the technology for industrial purposes.

Volumetric — 3D printed human tissue

Houston researchers are commercializing their organ 3D printing technology. Jordan Miller/Rice University

There may come a time when you or someone you love is in need of a new pair of lungs. Or perhaps it's a liver. It's not a scenario anyone dreams of, but thanks to Houston company Volumetric, you may never end up on a waiting list. Instead, that organ is made to order and 3D printed using a mix of medical plastics and human cells.

And this possibility isn't necessarily in the distant future. On the cover of the May 3 issue of the journal Science, is a contraption that looks a bit like a futuristic beehive. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. And it was crafted on a 3D printer in Jordan Miller's lab at Rice University. Miller and his bioengineering graduate student Bagrat Grigoryan are primed to profit from their inventions.

In 2018, they started Volumetric Inc., a company that sells both the hydrogel solutions used for printing organs like theirs and the printers themselves. Touring Miller's lab in the Houston Medical Center is a visual timeline of his team's progress designing printers. The version being manufactured is a slick little number, small enough to fit under chemical exhaust hoods, but fitted with everything necessary to print living tissues. It's made and sold in cooperation with CellInk, a larger bioprinting company.

"Our technology is based on projection," Miller told InnovationMap in May. Specifically, it's stereolithography, a type of 3D printing that produces the finished product layer-by-layer. Shining colored light of the right intensity turns the polymers into a solid gel.

Voyager — Email-less communication tool for maritime shipping

Voyager, a Houston SaaS company, has received fresh funds to develop its bulk shipping software. Tom Fisk/Pexels

Houston software startup Voyager is making waves in its quest to improve efficiency — and stem billions of dollars in losses — in the maritime bulk-shipping business. Now, it's got some fresh capital to help it achieve that mission.

InnovationMap reported in August that Houston-based Voyager revealed it secured $1.5 million in seed funding from four investors from around the world: Austin-based ATX Venture Partners, Houston- and California-based Blue Bear Capital, New York City-based GreenHawk Capital, and Oman-based Phaze Ventures. Previous investors include Boulder, Colorado-based Techstars and Spring-based Knightsgate Ventures.

With its software-as-a-service offering, Voyager aims to modernize the workflows of operators in the maritime bulk-commodities industry. The company says its technology will become more vital as autonomous shipping and internet- and Internet of Things-enabled cargo vessels grow in popularity. Voyager's technology enables all communication tied to a shipment to be handled via its web dashboard and app, essentially creating a one-stop shop for people who need to track messages about maritime bulk shipments.

"With Voyager, what it allows companies to do is essentially have all of those counter parties working together in a shared environment to manage the voyage together — entirely email free," Matthew Costello, CEO, tells InnovationMap in December.

Galen Data — cloud-based platform for connecting medical devices to the internet

Houston-based Galen Data is growing its clientbase and just formed two new partnerships with medical device companies. Photo via galendata.com

Educated as an engineer, Chris DuPont has stepped outside his professional comfort zone to generate funding for his Houston-based startup, Galen Data Inc. DuPont's pool of technical contacts in Houston is "wide and deep," he says, but his pool of financial contacts had been shallow.

Overcoming obstacles in Houston's business waters, DuPont has raised two rounds of angel funding — he declines to say how much — that have enabled Galen Data to develop and market its cloud-based platform for connecting medical devices to the internet, including pacemakers and glucose monitors. DuPont is the startup's co-founder and CEO.

Galen Data's patent-pending technology lets medical device manufacturers tailor the cloud-based software to their unique needs. DuPont says his company's software is geared toward medical devices that are outside, not inside, hospitals and other healthcare facilities. He declines to divulge how many customers the startup has.

Hatched within Houston-based Tietronix Software Inc., DuPont's previous employer, Galen Data launched in 2016 but didn't roll out its first product until 2018. Galen Data's emergence comes as the market for internet-connected mobile health apps keeps growing. One forecast envisions the global space for mobile health exceeding $94 billion by 2023.

"We want to be at the forefront of that technology curve," DuPont tells InnovationMap in May. "We might be six months early, we might be a year early, but it's starting to happen."

Houston researchers are commercializing their organ 3D printing technology. Jordan Miller/Rice University

Houston researchers are commercializing their human tissue-printing technology

3d-printed organs

There may come a time when you or someone you love is in need of a new pair of lungs. Or perhaps it's a liver. It's not a scenario anyone dreams of, but thanks to Houston company Volumetric, you may never end up on a waiting list. Instead, that organ is made to order and 3D printed using a mix of medical plastics and human cells.

And this possibility isn't necessarily in the distant future. On the cover of the May 3 issue of the journal Science, is a contraption that looks a bit like a futuristic beehive. It's a working air sac complete with blood vessels, the beginnings of a technology that is perhaps only a decade from being implanted in humans. And it was crafted on a 3D printer in Jordan Miller's lab at Rice University.

Yes, there are shades of another Houston story — Denton Cooley's implantation of the first artificial heart — but Cooley only inserted the organ. Miller and his bioengineering graduate student Bagrat Grigoryan are primed to profit from their inventions.

In 2018, they started Volumetric Inc., a company that sells both the hydrogel solutions used for printing organs like theirs and the printers themselves. Touring Miller's lab in the Houston Medical Center is a visual timeline of his team's progress designing printers. The version being manufactured is a slick little number, small enough to fit under chemical exhaust hoods, but fitted with everything necessary to print living tissues. It's made and sold in cooperation with CellInk, a larger bioprinting company.

"Our technology is based on projection," Miller explains. Specifically, it's stereolithography, a type of 3D printing that produces the finished product layer-by-layer. Shining colored light of the right intensity turns the polymers into a solid gel.

But why start a company when Miller and Grigoryan are already busy with research?

"If we want to do translational research, commercialization is important," reasons Miller. "We need to build the market to get that technology into the world."

Miller explains that usually the inventor of a technology is the best one to bring it to market.

"When we were building this technology in the lab we saw the potential for commercialization," he recalls. "We do see that this technology is highly scalable. We do think it can have a positive impact on tissue models in a lab."

Those tissue models could one day make not just scientists, but also animal rights activists, very happy. With the technology that Volumetric is developing, scientists could eventually print human cells so well that animal models would be far less accurate in predicting the success that the product being tested would have on humans.

As academics, though, Miller and Grigoryan weren't sure how to start a company. Fortunately, there is the National Science Foundation (NSF) and its I-Corps program. The pair spent a couple of weeks doing a regional program that taught scientists how to commercialize their technology.

"They want to see funded research get out of the lab," Miller says, explaining that they moved on to the national I-Corps program while Miller was on sabbatical from teaching at Rice, allowing them to interview potential customers.

This gave them the confidence to launch last year. Grigoryan now works full-time at the Med Center incubator and accelerator, Johnson & Johnson's JLabs. He has a team of two other scientists on staff.

"It would have been a lot harder to get started if we didn't have a space like JLabs available," Miller says. It also helps, he adds, that JLabs takes no equity, only helping the fledgling brand to finalize its market and get hooked in with potential investors.

Volumetric has its demo units ready to go and expects to start shipping printers in late June, pending final certifications.

"We believe we have technology to make organ replacements for people," Miller says.

And someday soon, long waits for a new set of lungs and a life of antirejection drugs could be a thing of the past.


Rice University bioengineers (from left) Bagrat Grigoryan, Jordan Miller and Daniel Sazer and collaborators created a breakthrough bioprinting technique that could speed development of technology for 3D printing replacement organs and tissues. Photo by Jeff Fitlow/Rice University

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.